Summit Therapeutics Inc (SMMT) concluded trading on Wednesday at a closing price of $4.43, with 4.1 million shares of worth about $18.18 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 120.40% during that period and On Wednesday, January 24 the price saw a gain of about 8.31%. Currently the company’s common shares owned by public are about 211.09M shares, out of which, 113.45M shares are available for trading.
Stock saw a price change of 32.24% in past 5 days and over the past one month there was a price change of 86.13%. Year-to-date (YTD), SMMT shares are showing a performance of 69.73% which decreased to -0.67% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.25 but also hit the highest price of $4.50 during that period. The average intraday trading volume for Summit Therapeutics Inc shares is 1.34 million. The stock is currently trading 46.57% above its 20-day simple moving average (SMA20), while that difference is up 77.15% for SMA50 and it goes to 118.72% higher than SMA200.
Summit Therapeutics Inc (NASDAQ: SMMT) currently have 211.09M outstanding shares and institutions hold larger chunk of about 4.66% of that.
The stock has a current market capitalization of $3.09B and its 3Y-monthly beta is at -1.15. It has posted earnings per share of -$1.58 in the same period. It has Quick Ratio of 1.80 while making debt-to-equity ratio of 1.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SMMT, volatility over the week remained 10.87% while standing at 9.85% over the month.
Analysts are in expectations that Summit Therapeutics Inc (SMMT) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter EPS is $0 and it is $0 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$1.24 in the same quarter a year ago.
